Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Diabetic peripheral and autonomic neuropathy

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

A new focal weakness, rapidly ascending sensory loss, sphincter disturbance, saddle anaesthesia, acute foot swelling, syncope with injury, persistent vomiting with ketosis, or painless myocardial-ischaemia symptoms is not routine chronic neuropathy. Assess urgently for stroke, spinal compression, Guillain–Barré syndrome, acute Charcot arthropathy, sepsis, DKA, arrhythmia or acute coronary syndrome. Autonomic neuropathy may mask tachycardia, pain or hypoglycaemia warning, so apparently mild symptoms can accompany serious physiological deterioration.

Synopsis

Detect diabetic nerve injury before ulceration or organ dysfunction, exclude treatable alternatives, relieve neuropathic pain safely, and protect function through multidisciplinary follow-up.

  • Distal symmetrical sensorimotor polyneuropathy usually begins in the toes with length-dependent numbness, burning, electric pain or loss of protective sensation.
  • A 10 g monofilament identifies loss of protective sensation but does not exclude small-fibre painful neuropathy when the result is normal.
  • Check pulses, skin, footwear, deformity, callus and previous ulcer at every formal foot assessment because neuropathy converts pressure into unnoticed injury.
  • Diabetes is common but not exclusive: consider vitamin B12 deficiency, alcohol, CKD, thyroid disease, medicines, paraproteinaemia, entrapment and inflammatory neuropathy.
  • Autonomic involvement can affect blood pressure, heart rate, sweating, stomach emptying, bowel habit, bladder, sexual function and awareness of hypoglycaemia.
  • Optimise glucose safely and address smoking, alcohol, blood pressure, lipids and nutrition; overly rapid glycaemic improvement can occasionally provoke acute painful neuropathy.
  • NICE offers amitriptyline, duloxetine, gabapentin or pregabalin as initial non-specialist options for neuropathic pain, selected by comorbidity and patient preference.
  • Review analgesic benefit by pain, sleep and function, and plan deprescribing; gabapentinoids carry dependence, withdrawal, sedation and respiratory-depression risks.

Key red flags

Atypical neurological pattern

Rapid evolution, pronounced weakness, asymmetry, a sensory level, cranial signs or sphincter change requires urgent neurological reassessment rather than routine diabetes follow-up.

Investigation priorities

01
Structured neurological foot examinationFirst step

Define distribution, protective sensation, motor involvement and immediate ulcer risk.

Management branches

ScreenFind neuropathy and foot risk

A person attends annual diabetes review or reports sensory symptoms, pain, balance change or unnoticed injury.

  1. Ask about pain, numbness, balance, falls, skin injury and footwear, then inspect both feet, palpate pulses and test protective sensation using the local NICE-aligned technique.
  2. Classify foot risk from neuropathy, vascular supply, deformity, callus, previous ulcer or amputation and renal replacement therapy, and arrange the required foot-protection follow-up.
  3. Give specific daily inspection, footwear and temperature-injury advice, with a same-day route for a new blister, colour change, swelling, break in skin or discharge.

Key medicines

DuloxetineFor licensed diabetic peripheral neuropathic pain, the starting and recommended maintenance dose is 60 mg once daily with or without food; review response after two months and follow the exact current product information.Avoid in hepatic impairment causing liver dysfunction, severe renal impairment and uncontrolled hypertension as specified by the SmPC. Review serotonergic interactions, bleeding risk, hyponatraemia, suicidality and withdrawal; taper rather than stopping suddenly.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG28 type 2 diabetes complicationsCurrent peripheral and autonomic neuropathy, gastroparesis, erectile dysfunction and foot-complication recommendations.
  • NICE NG17 type 1 diabetes recommendationsAnnual neuropathy review and organ-specific autonomic symptom guidance for adults.
  • NICE CG173 neuropathic pain recommendationsInitial medicine choices, switching, review and specialist referral in non-specialist care.
  • Duloxetine Summary of Product CharacteristicsLicensed diabetic neuropathic-pain dose, contraindications, precautions and discontinuation information.
  • MHRA strengthened gabapentinoid dependence warningsCurrent UK warnings on addiction, dependence, tolerance and withdrawal communication.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftAwaiting review
Clinical state
JurisdictionUnited Kingdom